reiter neutral rate po
lower revenu slightli rais out-year sale forecast modestli
stronger eu sale chang revis multipl slightli lower
po prior view key june catalyst us approv decis
biosimilar neulasta gener advair less like drive materi
estim revis drive multipl re-rat trade
discount teva remain neutral view upside/downsid ahead
upcom june catalyst rel balanc assum best worst case
outcom ultim believ risk one file
could delay view june catalyst carri risk timelin delay
downward ep revis ex thu would want see greater upsid
posit stock binari event base pure management feedback
complex gener product offer potenti market exclus owe higher cost
develop regulatori burden howev recent case weve observ
smaller-than-expect gener market opportun due sever factor includ fda
push multipl gener approv new product categori estrac cream
innov line extens strategi copaxon brand price eros advair
link thu make call go june catalyst believ investor
must convict time approv neulasta us brand
concern whether mylan/biocon get time approv fda full week
review correct plan submit manufactur partner biocon follow pre-
approv inspect delay program like assur launch alongsid one
addit competitor alreadi convert neulasta unit
proprietari onpro devic g-advair possibl first gener dry-powd inhal
note fda histor conserv inhal ics/laba
inhal market crater price pressur henc delay could mean enjoy
much shorter-term exclus g-advair b-neulasta alreadi healthi
contributor number limit upsid one two catalyst hit
upside/downsid assumpt page
net dbt
june catalyst time key valu
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
global pharmaceut compani
develop manufactur market
pharmaceut product span three segment
gener over-the-count brand specialti
product north american biggest market
account approxim total
sale follow europ
remaind rest world becom
one largest specialti gener player
combin organ growth
number signific acquisit
neutral balanc
invest posit neg stock
like prospect organ growth us
copaxon potenti upsid gener
approv advair restasi convers
concern around headwind gener
busi well aggress assumpt
compani guidanc impli cost
cut deal may may drive
long-term valu sharehold
conceptu exercis took look variou compon driver mylan
busi includ base busi key pipelin product g-advair b-neulasta
estim bull/bear case npv around pipelin catalyst drive
stock upside/downsid howev realiti investor look abil
get approv longer-dur complex gener valid
compani abil deliv flat slight organ growth follow sever
year growth key epipen price analysi assum
upcom june catalyst could best case drive multipl re-rat ebitda
vs teva well current howev wed
expect share remain discount multipl teva current trade
visibl durat predict teva key pipelin agent austedo
fremanezumab better vs less visibl competit dynam complex
base case assum underli base busi trade
ev/ebitda repres g-advair npv odd
assum sole gener maintain gener share
out-year npv account conting payment relat g-advair
liabil risk-adjust basi b-neulasta npv odd
assum peak biosimilar substitut peak gener discount peak
molecul share profit split
bear case downsid scenario assum mylan
underli base busi trade floor ev/ebitda follow meaning delay
program g-advair npv odd approv assum
delay year result multipl player within first market
format higher increment price discount b-neulasta npv
odd assum six-month delay result least one entrant format
increment price discount lower peak molecul share vs
bull case upsid scenario assum upward multipl
revis base busi line teva multipl
repres g-advair b-neulasta combin npv risk
po probabl success npv use wacc termin growth rate
chang po
chang current price
price object po base multipl ebitda
rel gener peer believ share trade
similar multipl gener peer lower closest peer teva latter
benefit low trough year uptick clinic de-risk spec
brand furthermor less visibl earn profil
view compani gener growth driver less durabl sourc growth
teva key spec brand believ dcf appropri valuat methodolog
littl visibl outlook beyond one two year
multipl take follow consider approv g-advair gener
advair relat conting payment mid-single-digit growth
eu row busi
risk po approv g-advair greater-than-expect competit
pressur copaxon gener
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
